Sangamo Therapeutics Inc Quick Ratio (SGMO) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sangamo Therapeutics Inc   (NASDAQ: SGMO)

Sangamo Therapeutics Inc 's Quick Ratio

SGMO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Sangamo Therapeutics Inc 's Cash & cash equivalent grew by 31.69 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Sangamo Therapeutics Inc 's Quick Ratio to 0.52, Quick Ratio remained below Sangamo Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 110 other companies have achieved higher Quick Ratio than Sangamo Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 2034, from total ranking in the fourth quarter 2025 at 2329.

Explain Quick Ratio?
How much Cash & cash equivalents SGMO´s has?
What are SGMO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SGMO Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 7.21 % -7.29 % 16.13 % 22.19 % 23.16 %
Y / Y Cash & cash equivalent Change 9.56 % -50.03 % -24.45 % 38 % -53.73 %
Quick Ratio MRQ 0.52 0.49 0.59 0.8 0.51
SGMO's Total Ranking # 2034 # 2329 # 1595 # 1599 # 1662
Seq. Current Liabilities Change 25.12 % -15.28 % 5.17 % -3.84 % 8.2 %
Seq. Cash & cash equivalent Change 31.69 % -29.27 % -22.76 % 52.28 % -39.93 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 111
Healthcare Sector # 667
Overall Market # 2034


Quick Ratio Statistics
High Average Low
18.58 6.23 0.49
(Mar 31 2016)   (Dec 31 2025)




Financial Statements
Sangamo Therapeutics Inc 's Current Liabilities $ 53 Millions Visit SGMO's Balance sheet
Sangamo Therapeutics Inc 's Cash & cash equivalent $ 28 Millions Visit SGMO's Balance sheet
Source of SGMO's Sales Visit SGMO's Sales by Geography


Cumulative Sangamo Therapeutics Inc 's Quick Ratio

SGMO's Quick Ratio for the trailling 12 Months

SGMO Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 8.93 % 12.84 % 2.49 % -3.92 % -14.88 %
Y / Y Cash & cash equivalent TTM Growth -13.12 % -30.15 % -18.94 % -21.36 % -55.19 %
Quick Ratio TTM 0.6 0.6 0.7 0.78 0.76
Total Ranking TTM # 2773 # 2959 # 3341 # 3131 # 2419
Seq. Current Liabilities TTM Growth 1.88 % -1.73 % 3.74 % 4.87 % 5.54 %
Seq. Cash & cash equivalent TTM Growth 2.11 % -15.53 % -6.63 % 7.87 % -17.9 %

Quick ratio ranking by company, industry and sector >> Back to SGMO Financial Strength Comparisons >> Go to Compare SGMO Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the growth in Current Liabilities in the Q1 2026 to $53.13 millions, cumulative Quick Ratio remained unchanged at 0.6 below the Sangamo Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 124 other companies have achieved higher Quick Ratio than Sangamo Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2773, from total ranking during the twelve months ending fourth quarter 2025 at 2959.

Explain Quick Ratio?
How much Cash & cash equivalents SGMO´s has?
What are SGMO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 125
Healthcare Sector # 786
Within the Market # 2773


trailing twelve months Quick Ratio Statistics
High Average Low
12.53 5.56 0.6
(Dec 31 2016)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Bio techne Corp  1.37 $ 209.819  Millions$ 153.278  Millions
Pelthos Therapeutics Inc   1.28 $ 31.976  Millions$ 25.003  Millions
Coherus Oncology inc   1.26 $ 167.048  Millions$ 132.332  Millions
Biocryst Pharmaceuticals Inc   1.22 $ 239.254  Millions$ 195.391  Millions
Sana Biotechnology Inc   1.17 $ 101.136  Millions$ 86.265  Millions
Curis Inc   1.09 $ 15.001  Millions$ 13.745  Millions
Armata Pharmaceuticals Inc   1.03 $ 4.754  Millions$ 4.635  Millions
Aim Immunotech Inc   1.00 $ 5.879  Millions$ 5.890  Millions
Lenz Therapeutics Inc   0.96 $ 24.772  Millions$ 25.806  Millions
Exozymes Inc   0.91 $ 1.445  Millions$ 1.582  Millions
Liminatus Pharma Inc   0.88 $ 1.908  Millions$ 2.167  Millions
Halozyme Therapeutics Inc   0.85 $ 309.749  Millions$ 363.210  Millions
Dbv Technologies S a   0.75 $ 42.600  Millions$ 56.796  Millions
Xtant Medical Holdings Inc   0.65 $ 12.137  Millions$ 18.773  Millions
Senti Biosciences Holdings Inc   0.63 $ 8.935  Millions$ 14.268  Millions
Silexion Therapeutics Corp  0.60 $ 2.440  Millions$ 4.060  Millions
Atlantic Coastal Acquisition Corp Ii  0.60 $ 5.453  Millions$ 9.117  Millions
Zeo Scientifix Inc   0.59 $ 1.846  Millions$ 3.111  Millions
Sangamo Therapeutics Inc   0.52 $ 27.586  Millions$ 53.134  Millions
Amgen Inc   0.48 $ 12,038.000  Millions$ 24,955.000  Millions
Biomx Inc  0.48 $ 1.168  Millions$ 2.447  Millions
Surrozen Inc   0.44 $ 106.910  Millions$ 243.155  Millions
Meiragtx Holdings Plc  0.41 $ 71.541  Millions$ 176.127  Millions
Biocardia Inc   0.34 $ 0.951  Millions$ 2.778  Millions
Biogen Inc   0.30 $ 900.000  Millions$ 2,998.900  Millions
Pluri Inc   0.29 $ 9.322  Millions$ 32.006  Millions
Viskase Holdings inc   0.25 $ 28.619  Millions$ 112.789  Millions
Champions Oncology Inc   0.24 $ 4.872  Millions$ 19.922  Millions
Outlook Therapeutics Inc   0.20 $ 7.748  Millions$ 38.884  Millions
Agenus Inc  0.14 $ 34.996  Millions$ 249.237  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.